Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Irene van Heuvel"'
Autor:
Saskia M. Wilting, Joost L.M. Jongen, Stefan Sleijfer, Ellen Heitzer, Eric M.J. Bindels, Johan M. Kros, Peter A.E. Sillevis Smitt, Martin J. van den Bent, Irene van Heuvel, Vanja de Weerd, John W.M. Martens, Agnes Jager, Teoman Deger, Lindsay Angus
Correlation between input ng cfDNA in the Oncomine Breast V2 breast panel and the median molecular coverage (i.e., the median number of uniquely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3243e25d14721db63322abda8705989f
https://doi.org/10.1158/1078-0432.22478543.v1
https://doi.org/10.1158/1078-0432.22478543.v1
Autor:
Saskia M. Wilting, Joost L.M. Jongen, Stefan Sleijfer, Ellen Heitzer, Eric M.J. Bindels, Johan M. Kros, Peter A.E. Sillevis Smitt, Martin J. van den Bent, Irene van Heuvel, Vanja de Weerd, John W.M. Martens, Agnes Jager, Teoman Deger, Lindsay Angus
Purpose:Detection of leptomeningeal metastasis is hampered by limited sensitivities of currently used techniques: MRI and cytology of cerebrospinal fluid (CSF). Detection of cell-free tumor DNA in CSF has been proposed as a tumor-specific candidate t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::039efe861a64cb777fa53fec79471ee0
https://doi.org/10.1158/1078-0432.c.6529979.v1
https://doi.org/10.1158/1078-0432.c.6529979.v1
Autor:
Saskia M. Wilting, Joost L.M. Jongen, Stefan Sleijfer, Ellen Heitzer, Eric M.J. Bindels, Johan M. Kros, Peter A.E. Sillevis Smitt, Martin J. van den Bent, Irene van Heuvel, Vanja de Weerd, John W.M. Martens, Agnes Jager, Teoman Deger, Lindsay Angus
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ced7184ead7700c9dabd2683a3a82b5a
https://doi.org/10.1158/1078-0432.22478549.v1
https://doi.org/10.1158/1078-0432.22478549.v1
Autor:
Martin J. van den Bent, Irene van Heuvel, John W.M. Martens, Peter A. E. Sillevis Smitt, Lindsay Angus, Ellen Heitzer, Agnes Jager, Vanja de Weerd, Joost L.M. Jongen, Saskia M Wilting, Stefan Sleijfer, Teoman Deger, Eric M.J. Bindels, Johan M. Kros
Publikováno v:
Clinical Cancer Research, 27(10), 2798-2806. American Association for Cancer Research Inc.
Purpose: Detection of leptomeningeal metastasis is hampered by limited sensitivities of currently used techniques: MRI and cytology of cerebrospinal fluid (CSF). Detection of cell-free tumor DNA in CSF has been proposed as a tumor-specific candidate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca1ccdc4dd89fc871d0c77153a405de7
https://pure.eur.nl/en/publications/6a058c21-703c-4e80-bf69-96ced24c50fd
https://pure.eur.nl/en/publications/6a058c21-703c-4e80-bf69-96ced24c50fd
Autor:
Anja Gijtenbeek, Vassilis Golfinopoulos, Michael Weller, Sarah Pascoe, Roger Stupp, Sara Erridge, Irene van Heuvel, Marc Sanson, Winand N.M. Dinjens, Hendrikus J. Dubbink, Warren P. Mason, David Brachman, Martin J. van den Bent, Robert B. Jenkins, Peter Hau, Wolfgang Wick, Thierry Lesimple, Susan Clenton, Matthew E. Griffin, Jean Francais Baurain, Brigitta G. Baumert, Sanjeev Gill, Roelien H. Enting, Walter Taal, Damien C. Weber, Kenneth Aldape, Pieter Wesseling, Roberta Rudà, Catherine McBain, Helen Wheeler, Sarah Nuyens, Johan M. Kros, Anna K. Nowak, Paul Clement, Frédéric Dhermain, Thierry Gorlia, Ulrich Herrlinger, Olivier Chinot, Jaap C. Reijneveld, Alba A. Brandes, Michael A. Vogelbaum
Publikováno v:
The Lancet, 390(10103), 1645-1653. Elsevier Limited
The Lancet, 390(10103), 1645-1653. ELSEVIER SCIENCE INC
van den Bent, M J, Baumert, B, Erridge, S C, Vogelbaum, M A, Nowak, A K, Sanson, M, Brandes, A A, Clement, P M, Baurain, J F, Mason, W P, Wheeler, H, Chinot, O L, Gill, S, Griffin, M, Brachman, D G, Taal, W, Rudà, R, Weller, M, McBain, C, Reijneveld, J, Enting, R H, Weber, D C, Lesimple, T, Clenton, S, Gijtenbeek, A, Pascoe, S, Herrlinger, U, Hau, P, Dhermain, F, van Heuvel, I, Stupp, R, Aldape, K, Jenkins, R B, Dubbink, H J, Dinjens, W N M, Wesseling, P, Nuyens, S, Golfinopoulos, V, Gorlia, T, Wick, W & Kros, J M 2017, ' Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma : A phase 3, randomised, open-label intergroup study ', The Lancet, vol. 390, no. 10103, pp. 1645-1653 . https://doi.org/10.1016/S0140-6736(17)31442-3
Lancet, 390(10103), 1645-1653. Elsevier Limited
The Lancet (London), 390, 1645-1653
Lancet (UK), 390(10103), 1645-1653. Elsevier Ltd.
Lancet, 390(10103), 1645-1653. Elsevier Science
The Lancet (London), 390, 10103, pp. 1645-1653
The Lancet, 390(10103), 1645-1653. ELSEVIER SCIENCE INC
van den Bent, M J, Baumert, B, Erridge, S C, Vogelbaum, M A, Nowak, A K, Sanson, M, Brandes, A A, Clement, P M, Baurain, J F, Mason, W P, Wheeler, H, Chinot, O L, Gill, S, Griffin, M, Brachman, D G, Taal, W, Rudà, R, Weller, M, McBain, C, Reijneveld, J, Enting, R H, Weber, D C, Lesimple, T, Clenton, S, Gijtenbeek, A, Pascoe, S, Herrlinger, U, Hau, P, Dhermain, F, van Heuvel, I, Stupp, R, Aldape, K, Jenkins, R B, Dubbink, H J, Dinjens, W N M, Wesseling, P, Nuyens, S, Golfinopoulos, V, Gorlia, T, Wick, W & Kros, J M 2017, ' Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma : A phase 3, randomised, open-label intergroup study ', The Lancet, vol. 390, no. 10103, pp. 1645-1653 . https://doi.org/10.1016/S0140-6736(17)31442-3
Lancet, 390(10103), 1645-1653. Elsevier Limited
The Lancet (London), 390, 1645-1653
Lancet (UK), 390(10103), 1645-1653. Elsevier Ltd.
Lancet, 390(10103), 1645-1653. Elsevier Science
The Lancet (London), 390, 10103, pp. 1645-1653
Item does not contain fulltext BACKGROUND: The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumou
Autor:
Winand N.M. Dinjens, Jacoline E C Bromberg, Carin C.D. van der Rijt, Peter A. E. Sillevis Smitt, Irene van Heuvel, Agnes A. A. C. M. Wertenbroek, Johan M. Kros, Walter Taal, Martin J. van den Bent
Publikováno v:
Journal of Neuro-Oncology, 121(2), 365-372. Kluwer Academic
We treated patients with newly diagnosed and large low-grade oligodendroglial tumors with upfront procarbazine, CCNU and vincristine (PCV) in order to delay radiotherapy. Patients were treated with PCV for a maximum of 6 cycles. The response to treat
Autor:
HM Oosterkamp, Jan Buter, Annemiek M E Walenkamp, Hendrikus J. Dubbink, Irene van Heuvel, Franchette W P J van den Berkmortel, Filip de Vos, Dolf Boerman, Rob L. H. Jansen, Bronno van der Holt, Laurens V. Beerepoot, Martin J. van den Bent, Dieta Brandsma, Winand N.M. Dinjens, Martin J B Taphoorn, Jacoline E C Bromberg, Roelien H. Enting, René M. Vernhout, Monique Hanse, Aafke H. Honkoop, Walter Taal
Publikováno v:
Lancet Oncology, 15(9), 943-953. ELSEVIER SCIENCE INC
Lancet oncology, 15(9), 943-953. Elsevier Science
Taal, W, Oosterkamp, H M, Walenkamp, A M E, Dubbink, H J, Beerepoot, L V, Hanse, M C J, Buter, J, Honkoop, A H, Boerman, D, de Vos, F Y F, Dinjens, W N M, Enting, R H, Taphoorn, M J B, van den Berkmortel, F W P J, Jansen, R L H, Brandsma, D, Bromberg, J E C, van Heuvel, I, Vernhout, R M, van der Holt, B & van den Bent, M J 2014, ' Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial ', Lancet Oncology, vol. 15, no. 9, pp. 943-953 . https://doi.org/10.1016/S1470-2045(14)70314-6
Lancet Oncology, 15(9), 943-953. Lancet Publishing Group
Lancet oncology, 15(9), 943-953. Elsevier Science
Taal, W, Oosterkamp, H M, Walenkamp, A M E, Dubbink, H J, Beerepoot, L V, Hanse, M C J, Buter, J, Honkoop, A H, Boerman, D, de Vos, F Y F, Dinjens, W N M, Enting, R H, Taphoorn, M J B, van den Berkmortel, F W P J, Jansen, R L H, Brandsma, D, Bromberg, J E C, van Heuvel, I, Vernhout, R M, van der Holt, B & van den Bent, M J 2014, ' Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial ', Lancet Oncology, vol. 15, no. 9, pp. 943-953 . https://doi.org/10.1016/S1470-2045(14)70314-6
Lancet Oncology, 15(9), 943-953. Lancet Publishing Group
BACKGROUND: Treatment options for recurrent glioblastoma are scarce, with second-line chemotherapy showing only modest activity against the tumour. Despite the absence of well controlled trials, bevacizumab is widely used in the treatment of recurren
Autor:
Irene van Heuvel, Peter A. E. Sillevis Smitt, Johan M. Kros, Joyce M. W. Segers-van Rijn, Walter Taal, Martin J. van den Bent, Jacoline E C Bromberg, Carin C.D. van der Rijt
Publikováno v:
Journal of Neuro-Oncology, 108(1), 195-200. Kluwer Academic
Journal of Neuro-Oncology
Journal of Neuro-Oncology
Alternative temozolomide regimens have been proposed to overcome O(6)-methylguanine-DNA methyltransferase mediated resistance. We investigated the efficacy and tolerability of 1 week on/1 week off temozolomide (ddTMZ) regimen in a cohort of patients
Autor:
Jacoline E C Bromberg, Irene van Heuvel, Winand N.M. Dinjens, Walter Taal, Martin J. van den Bent, Willem Boogerd, Floris H. Groenendijk, Tjeerd J. Postma, Johan M. Kros, Hendrikus J. Dubbink, Bronno van der Holt, Chris B.L. Zonnenberg, Ronald van Marion, Peter A. E. Sillevis Smitt, Bernard A. Zonnenberg, J.M.M. Gijtenbeek, Mathilde C.M. Kouwenhoven
Publikováno v:
Neuro-Oncology, 13, 235-41
Neuro-Oncology, 13, 2, pp. 235-41
Taal, W, Dubbink, H J, Zonnenberg, C B L, Zonnenberg, B A, Postma, T J, Gijtenbeek, J M M, Boogerd, W, Groenendijk, F H, Kros, J M, Kouwenhoven, M C M, van Marion, R, van Heuvel, I, van der Holt, B, Bromberg, J E C, Smitt, P A E S, Dinjens, W N M & van den Bent, M J 2011, ' First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response ', Neuro-Oncology, vol. 13, no. 2, pp. 235-241 . https://doi.org/10.1093/neuonc/noq177
Neuro-Oncology, 13(2), 235-241. Oxford University Press
Neuro-Oncology, 13, 2, pp. 235-41
Taal, W, Dubbink, H J, Zonnenberg, C B L, Zonnenberg, B A, Postma, T J, Gijtenbeek, J M M, Boogerd, W, Groenendijk, F H, Kros, J M, Kouwenhoven, M C M, van Marion, R, van Heuvel, I, van der Holt, B, Bromberg, J E C, Smitt, P A E S, Dinjens, W N M & van den Bent, M J 2011, ' First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response ', Neuro-Oncology, vol. 13, no. 2, pp. 235-241 . https://doi.org/10.1093/neuonc/noq177
Neuro-Oncology, 13(2), 235-241. Oxford University Press
Diffuse infiltrating low-grade glioma (LGG; WHO grade II tumors) constitute approximately 10–20% of primary brain tumors in adults and primarily occur in young adults.1 The majority of LGGs are low-grade diffuse astrocytomas (LGAs). Although LGAs a
Autor:
Irene van Heuvel, Martin J. van den Bent, Karin van der Rijt, Winand N.M. Dinjens, Walter Taal, Johan M. Kros, Jacoline E C Bromberg, Peter A. E. Sillevis Smitt, Agnes A. A. C. M. Wertenbroek
PURPOSE: We treated patients with newly diagnosed and large low-grade oligodendroglial tumors with upfront procarbazine, lomustine (CCNU) and vincristine (PCV) in our institution in order to delay RT. We now report long term follow-up on a cohort of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::336ab1305b6b79adcc0c69c62cd924ed
https://europepmc.org/articles/PMC4217836/
https://europepmc.org/articles/PMC4217836/